BackArcturus Therapeutics Holdings Overview
Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Target Price

See Arcturus Therapeutics Holdings's analyst price targets ($41) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$14.12

Average Target Price

$41.00190.4% upside

1 analysts in the last 4 months

High: $41 | Low: $41

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-02Roth Capital$41190.4% upsideOpen
2026-03-04Piper SandlerYasmeen Rahimi$2577.1% upsideOpen
2026-01-22Roth Capital$2041.6% upsideOpen
2025-08-22Leerink PartnersLili Nsongo$54282.4% upsideOpen
2025-05-28ScotiabankGreg Harrison$32126.6% upsideOpen
2025-03-10BTIGThomas Shrader$48239.9% upsideOpen
2024-11-11Canaccord GenuityWhitney Ijem$10.5825.1% downsideOpen
2024-08-06Canaccord GenuityWhitney Ijem$10.327.1% downsideOpen
2024-07-02H.C. WainwrightEd Arce$8.5839.2% downsideOpen
2024-05-31Piper SandlerYasmeen Rahimi$20.0241.8% upsideOpen
2024-05-10Canaccord GenuityWhitney Ijem$12.312.9% downsideOpen
2024-03-19LaidlawYale Jen$11.320% downsideOpen
2022-11-02BarclaysGena Wang$2577.1% upsideOpen
2022-05-11Goldman Sachs$140.8% downsideOpen
2021-11-09Goldman SachsMadhu Kumar$30112.5% upsideOpen

Arcturus Therapeutics Holdings (ARCT) FAQ

Arcturus Therapeutics Holdings's target price stands at $41. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $41 for ARCT implies 190.4% upside versus today's price ($14.12). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Arcturus Therapeutics Holdings's target price evolved across reporting periods, while the comparison chart places ARCT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Arcturus Therapeutics Holdings's reading of $41 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.